Title: Imaging and Inhibitor Probe for Alzheimer's disease Diagnostic and Treatment
Acronym: I2PAD
Cod: ERANET-EURONANOMED-3-I2PAD
Contract Number: 281
Period: 01.01.2022-31.12.2024

To develop innovative treatments to stem the evolutionary nature of AD pathologies, employing proteins targeting the auto-aggregative processes. Future treatments combined with new early diagnosis strategies would then make it possible to progress in the care of these pathologies. We propose to design theranostic probes which will be synthesized and preclinically evaluated within the consortium. The selected structures proved to inhibit Tau’s fibrillation, are based on hexapeptide inhibitors targeting Tau’s nucleation steps, radiolabeled with 64Cu/44Sc. The hexapeptides will be synthesized by consortium partners while our group will produce the selected radioisotope, optimize the radiolabeling strategy and participate to preclinical investigations, both in vitro and in vivo.